Combatting these killers are companies like Anixa Biosciences (NASDAQ:ANIX), a biotech company leading the fight against cancer and infectious disease through therapies and vaccines. The company currently reports having four solutions in development, including:
Anixa tells Benzinga it has made several advancements in its projects in 2022.
Bites By Numbers
According to data given to Benzinga, Anixa Biosciences:
Anixa Biosciences recently announced clinical trials for its CAR-T ovarian cancer treatment in addition to the breast cancer vaccine trial the Company is already engaged in.
Click here to keep track of Anixa’s story
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by Julia Koblitz on Unsplash
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
